Retatrutide Intelligence

Research update

Lancet (London, England)

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

BACKGROUND: Retatrutide is an agonist of GIP, GLP-1, and glucagon receptors, and is currently under investigation for the treatment of obesity, type 2 diabetes, and other comorbidities, including knee osteoarthritis and obstructive sleep apnoea. We aimed to assess the efficacy and safety of retatrutide in adults with obesity and type 2 diabetes.

10 Oct 2026

Indexed from PubMed

Official source updatemedium

Eli Lilly and Company

Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes

In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half no longer meeting the BMI criteria for obesity Participants with a baseline BMI of 35 or higher who took retatrutide 12 mg lost up to an

29 Sept 2026

Confirmed against source document

Official source updatehigh

Eli Lilly and Company

Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health

Pivotal results from TRIUMPH-2 showed retatrutide, an investigational triple hormone receptor agonist, delivered substantial weight loss and A1C improvements in obesity and type 2 diabetes Findings from ACHIEVE-4, the largest and longest study of Foundayo in type 2 diabetes, reaffirmed its safety

15 Sept 2026

Confirmed against source document

See How Retatrutide Works →

Status Dashboard

Retatrutide development status

A consolidated view of the compound's development stage, regulatory standing and next expected milestone.

Development Timeline

Last verified: 18 Oct 2026

✓
Discovery
Complete
✓
Phase 1
Complete
✓
Phase 2
Complete
Phase 3
Current
FDA Submission
Pending
FDA Review
Pending
Approval
Pending

Current stage

Phase 3

Next milestone

Company plans BLA submission in Q1 2027 (company-planned, not yet filed; not FDA approved)

Expected timing

Company plans BLA submission in Q1 2027 (company-planned, not yet filed; not FDA approved)

Last development

Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes

Last verified

18 Oct 2026

Source

Eli Lilly and Company

Compound Record

Developer: Eli Lilly and Company
Compound: Retatrutide
Compound code: LY3437943
Mechanism: GLP-1 / GIP / Glucagon receptor agonist
Development Stage: Phase 3
FDA Approved: No
Regulatory Status: Investigational
Next Expected Milestone: Company plans BLA submission in Q1 2027 (company-planned, not yet filed; not FDA approved)
Primary Source: Eli Lilly and Company
Latest Source Check: 18 Oct 2026
Last Updated: 4 Sept 2026

Mechanism

Why is retatrutide different?

Simplified receptor-level overview

Investigational — not FDA approved

Retatrutide

LY3437943

single investigational molecule

Clinical assessment

Outcomes measured in clinical trials

Body weight
A1C
Safety/tolerability

The diagram shows receptor targets and studied biological pathways, not guaranteed individual outcomes.

What Changed

What changed in the record

Counts of source-detected changes stored in the database. Every figure comes from a recorded registry, literature or regulatory event.

View Change History

Today

Clinical trial changes: 0
New publications: 0
Regulatory developments: 0

Last 7 days

Clinical trial changes: 0
New publications: 0
Regulatory developments: 0

Trial Registry

Retatrutide Clinical Trial Tracker

Registered studies across obesity, type 2 diabetes and related indications, with status and completion timing.

View All Clinical Trials

TRIUMPH-5
ID
NCT06662383
Phase
Phase 3
Status
Active, not recruiting
Primary completion
1 Nov 2026
Indication
Obesity
TRIUMPH-8
ID
NCT07232719
Phase
Phase 3
Status
Active, not recruiting
Primary completion
1 Jul 2027
Indication
Obesity, Overweight
TRIUMPH-7
ID
NCT07035093
Phase
Phase 3
Status
Active, not recruiting
Primary completion
1 Sept 2027
Indication
Obesity, Overweight, Chronic Low Back Pain (CLBP)
TRIUMPH-6
ID
NCT06859268
Phase
Phase 3
Status
Active, not recruiting
Primary completion
1 Apr 2028
Indication
Obesity
TRIUMPH-9
ID
NCT07357415
Phase
Phase 3
Status
Active, not recruiting
Primary completion
1 Oct 2028
Indication
Obesity, Overweight
TRIUMPH-2
ID
NCT05929079
Phase
Phase 3
Status
Completed
Primary completion
16 Jun 2026
Indication
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea

Trial	ClinicalTrials.gov ID	Indication	Phase	Enrolment	Status	Primary Completion	Last Updated	Verification
TRIUMPH-5	NCT06662383	Obesity	Phase 3	800	Active, not recruiting	1 Nov 2026	23 Oct 2026	Verified
TRIUMPH-8	NCT07232719	Obesity, Overweight	Phase 3	250	Active, not recruiting	1 Jul 2027	23 Oct 2026	Verified
TRIUMPH-7	NCT07035093	Obesity, Overweight, Chronic Low Back Pain (CLBP)	Phase 3	586	Active, not recruiting	1 Sept 2027	23 Oct 2026	Verified
TRIUMPH-6	NCT06859268	Obesity	Phase 3	643	Active, not recruiting	1 Apr 2028	23 Oct 2026	Verified
TRIUMPH-9	NCT07357415	Obesity, Overweight	Phase 3	600	Active, not recruiting	1 Oct 2028	23 Oct 2026	Verified
TRIUMPH-2	NCT05929079	Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea	Phase 3	1,152	Completed	16 Jun 2026	23 Oct 2026	Verified

View all clinical trials →

Records are shown exactly as stored in the Retatrutide Report database. A record is marked verified only once a source and a verification timestamp have been recorded.

Regulatory

Retatrutide FDA Approval Tracker

Progress through the United States regulatory sequence. Stages advance only when an official FDA record has been detected and confirmed against its source document.

✓
Phase 3 programme
14 verified Phase 3 registry records
FDA submission
Not confirmed by an official source
Filing acceptance
Not confirmed by an official source
FDA review
Not confirmed by an official source
FDA decision
Not confirmed by an official source
Commercial launch
Not confirmed by an official source

Current confirmed stage: Phase 3 programme
Latest official development: Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
Development date: 29 Sept 2026
Source: Eli Lilly and Company — https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-substantial-weight
Last source check: 23 Oct 2026
Approval status: Not approved by the FDA

Company-planned milestone

Lilly plans to submit a biologics license application (BLA) in Q1 2027. The application has not yet been filed, and this is not an approval date. Source: Eli Lilly announcement

Results Explorer

Verified Phase 3 Results

A preview of verified efficacy endpoints. Filter every verified value by trial, dose, endpoint and duration in the full explorer.

Results from different trials should not be compared directly because populations, study designs, treatment durations, endpoints and analysis methods may differ.

TRIUMPH-2 · 12 mg
-20.8%
Mean change in body weight
80 weeks · Efficacy estimand
Peer-reviewed Phase 3
What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRIUMPH-3 · 12 mg
-22.6%
Mean change in body weight
80 weeks · Efficacy estimand
Sponsor topline result
What this means
The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records.
Figure / record sourceLast verified 30 Sept 2026
TRIUMPH-1 · 12 mg
-28.3%
Mean change in body weight
80 weeks · Efficacy estimand
Peer-reviewed Phase 3
What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026
TRANSCEND-T2D-1 · 12 mg
-16.8%
Mean change in body weight
40 weeks · Efficacy estimand
Peer-reviewed Phase 3
What this means
A verified peer-reviewed Phase 3 trial publication is linked. These figures still come from the sponsor release, not that publication.
Figure / record sourceLast verified 30 Sept 2026
Peer-reviewed publicationLast verified 13 Oct 2026

Open the full Results Explorer (29 verified results) →

Literature

Latest Retatrutide Research

Peer-reviewed publications covering pharmacology, efficacy and safety of retatrutide.

View all research

OtherPMID 42745421

Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.

Carneiro GRA, da Costa Nunes IK, Dos Santos Cardoso GR, Dos Santos PF, Padilha MC, Nogueira FCS, Pereira HMG

Rapid communications in mass spectrometry : RCM · Journal issue: 15 Dec 2026

Abstract excerpt

RATIONALE: Retatrutide (LY3437943) is a novel long-acting triple incretin receptor agonist that targets the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR).

Clinical trial resultsPMID 42608321

Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.

Ruotolo G, Harris C, Lin Y, Wilson JM, Pirro V, Duffin KL, Thomas MK, Hartman ML, Neill CO, Coskun T, Milicevic Z, Haupt A, Sattar N, Nicholls SJ

Diabetes, obesity & metabolism · Published online: 17 Aug 2026

Abstract excerpt

AIMS: To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D). MATERIALS AND METHODS: Data were analysed from two randomised, double-blind, placebo-controlled phase 2 trials.

OtherPMID 42603384

Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.

Tong LH, Leung KK, Hung CT

Journal of chromatography. A · 11 Oct 2026

Clinical trial resultsPMID 42810372

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, Eyde S, Park SY, Ferro J, Johnson C, Taylor A

Lancet (London, England) · 10 Oct 2026

Abstract excerpt

OtherPMID 42849462

Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?

Holst JJ

Lancet (London, England) · 10 Oct 2026

Competitive Landscape

How Retatrutide Compares

Side-by-side reference notes on mechanism, development stage and reported efficacy across leading candidates.

Cross-trial comparisons should be interpreted cautiously because study populations, trial designs, treatment durations and endpoints may differ.

Retatrutide vs Tirzepatide

Developer: Eli Lilly and CompanyEli Lilly and Company
Mechanism: GLP-1 / GIP / Glucagon triple agonistGLP-1 / GIP dual agonist
Administration: Once-weekly subcutaneousOnce-weekly subcutaneous
Development Stage: Phase 3Approved (obesity, type 2 diabetes)
Studied Population: Obesity ± type 2 diabetesObesity, type 2 diabetes, OSA
Regulatory Status: InvestigationalApproved

Retatrutide vs Semaglutide

Developer: Eli Lilly and CompanyNovo Nordisk
Mechanism: GLP-1 / GIP / Glucagon triple agonistGLP-1 receptor agonist
Administration: Once-weekly subcutaneousOnce-weekly subcutaneous or oral
Development Stage: Phase 3Approved (obesity, type 2 diabetes)
Studied Population: Obesity ± type 2 diabetesObesity, type 2 diabetes, CV risk
Regulatory Status: InvestigationalApproved

Retatrutide vs CagriSema

Developer: Eli Lilly and CompanyNovo Nordisk
Mechanism: GLP-1 / GIP / Glucagon triple agonistAmylin analogue + GLP-1 agonist
Administration: Once-weekly subcutaneousOnce-weekly subcutaneous
Development Stage: Phase 3Phase 3 / regulatory submission
Studied Population: Obesity ± type 2 diabetesObesity, type 2 diabetes
Regulatory Status: InvestigationalInvestigational

Retatrutide vs Amycretin

Developer: Eli Lilly and CompanyNovo Nordisk
Mechanism: GLP-1 / GIP / Glucagon triple agonistAmylin + GLP-1 receptor co-agonist
Administration: Once-weekly subcutaneousSubcutaneous or oral (in development)
Development Stage: Phase 3Phase 2
Studied Population: Obesity ± type 2 diabetesOverweight and obesity
Regulatory Status: InvestigationalInvestigational

Retatrutide vs MariTide